Disposition of DN-2327,a New Anxiolytic, in Rats, Dogs, and Monkeys
スポンサーリンク
概要
- 論文の詳細を見る
The disposition of DN-2327 after oral dosing of ^<14>C-labeled DN-2327 ([^<14>C]DN-2327) to rats, dogs and monkeys was studied. DN-2327 was absorbed from the small intestine after oral administration. In the plasma of these animals, a small amount of unchanged compound and M-I were detected, with M-II (a pharmacologically active metabolite) as a major component. The concentration of the unchanged compound in rat plasma attained a peak (C_<max>0.002μg/ml), then declined, with a half-life (t_<1/2>) of 3 h. T_<tax>, C_<max> and t_<1/2> of DN-2327 in dogs and monkeys were 0.6 h, 0.332μg/ml and 1.5h, and 2.3h, 0.036μg/ml and 6.2h, respectively. About 60,75 and 48% of the radioactivity dosed was absorbed in rats, dogs and monkeys, respectively, whereas the bioavailability in rats, dogs and monkeys was less than 1,34 and 10%, respectively, indicating that DN-2327 had been subjected to the first pass effect. In rats given [^<14>C] DN-2327 orally, the radioactivity was distributed widely in various tissues, including the brain. In the brain regions, DN-2327 and M-II were distributed and M-II was major component, indicating that the pharmacological effects of DN-2327 may depend largely on M-II. In these animals, [^<14>C] DN-2327 was excreted in feces via bile mostly as metabolites. During repeated oral administration, DN-2327 and its metabolites did not accumulate in rat tissues, except in the kidney.
- 公益社団法人日本薬学会の論文
- 1995-02-15
著者
-
吉田 清志
Drug Analysis And Pharmacokinetics Research Laboratories Pharmaceutical Development Division Takeda
-
近藤 孝浩
Drug Analysis And Pharmacokinetics Research Laboratories Pharmaceutical Development Division Takeda
-
倉田 百合子
Drug Analysis and Pharmacokinetics Research Laboratories, Pharmaceutical Development Division, Taked
-
吉村 義信
Drug Analysis and Pharmacokinetics Research Laboratories, Pharmaceutical Development Division, Taked
-
吉村 義信
Drug Analysis And Pharmacokinetics Research Laboratories Pharmaceutical Development Division Takeda
-
Yoshimura Yoshinobu
Drug Analysis And Pharmacokinetics Research Laboratories Pharmaceutical Development Division Takeda
-
倉田 百合子
Drug Analysis And Pharmacokinetics Research Laboratories Pharmaceutical Development Division Takeda
関連論文
- Rearrangement in Dihydroresorcinol Derivatives. XI. Photolysis and Thermolysis of 3-Azido-2-cyclohexen-1-ones and 2-Cyclopenten-1-ones
- Disposition of DN-2327,a New Anxiolytic, in Rats, Dogs, and Monkeys
- Degradation Products Generated by Sonication of Benzyl Alcohol, a Sample Preparation Solvent for the Determination of Residual Solvents in Pharmaceutical Bulks, on Capillary Gas Chromatography
- Double column-switching high-performance liquid chromatographic method for the determination of TAK-603 and its metabolites in human serum
- Enantioselective determination of pazinaclone, a new isoindoline anxiolytic, and its active metabolite in rat plasma by high-performance liquid chromatography
- Rearrangement in Dihydroresorcinol Derivatives. VII. Curtius Rearrangement of 3-Azido-2-cyclohexen-1-ones and a Ring Contraction of 2-Alkoxy-4,5,6,7-tetrahydro-1H-azepin-4-ones
- Imine-enamine Tautomerism and Ring Contration of 2-Methoxy-4,5,6,7-tetrahydro-1H-azepin-4-ones